TY - JOUR
T1 - Effect of stressful life events on subclinical psychotic symptoms in first-degree relatives and healthy controls
AU - Lachowicz, Aleksandra M.
AU - Vaessen, Thomas
AU - van Aubel, Evelyne
AU - Butjosa, Anna
AU - Reininghaus, Ulrich
AU - Myin-Germeys, Inez
AU - van Amelsvoort, Therese
AU - Bartels-Velthuis, Agna A.
AU - Bruggeman, Richard
AU - Cahn, Wiepke
AU - de Haan, Lieuwe
AU - Schirmbeck, Frederike
AU - Simons, Claudia J. P.
AU - GROUP Investigators are:
AU - van Os, Jim
N1 - Funding Information: AML is supported by a Doctoral Fellowship grant from Research Foundation Flanders ( FWO 11J8221N ). TV is supported by a Postdoctoral Fellowship grant from Research Foundation Flanders ( FWO 1243620N ). IMG is supported by a Research Foundation Flanders Odysseus grant ( FWO GOF8416N ), which also includes the PhD studentships of EVA. UR is supported by NWO VENI grant ( 451-13-022 ) and a DFG Heisenberg professorship ( 389624707 ). Funding Information: The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (Zon-Mw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal and Delta.) Publisher Copyright: © 2022 Elsevier B.V.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Exposure to Stressful Life Events (SLEs) has been linked to psychosis. However, the combined effect of SLEs and familial risk on subclinical psychotic symptoms over time remains unknown. The objective of the present study was to investigate the effect of SLEs on the level of subclinical psychotic symptoms in individuals with and without familial vulnerability for psychosis. Data were collected from siblings of individuals diagnosed with psychotic disorder and healthy controls at baseline (N = 293) and three years later at follow-up (N = 928). We assessed self-reported and observer-rated subclinical positive, negative, and depressive psychotic symptoms. Participants reported the number of SLEs in the preceding 6 months. A multilevel multivariate regression analysis revealed a positive association between the retrospectively assessed number of SLEs and symptom levels, regardless of vulnerability status (p <. 001 for all outcomes). The prospective analysis demonstrated that exposure to SLEs at baseline predicted higher levels of subclinical psychotic symptoms at follow-up. However, after controlling for the level of symptoms at baseline, these associations were no longer significant. Again, the vulnerability status did not modify these results. Nevertheless, siblings in our sample were approximating the end of the critical period for the development of psychotic disorder (mean age at baseline M = 29 and follow-up M = 34). The findings partly support the vulnerability-stress model of psychosis, yet do not confirm the role of familial risk in this association. SLEs may represent a risk factor for psychosis at a population level, thus supporting the continuity of the psychosis spectrum in terms of associated risk factors.
AB - Exposure to Stressful Life Events (SLEs) has been linked to psychosis. However, the combined effect of SLEs and familial risk on subclinical psychotic symptoms over time remains unknown. The objective of the present study was to investigate the effect of SLEs on the level of subclinical psychotic symptoms in individuals with and without familial vulnerability for psychosis. Data were collected from siblings of individuals diagnosed with psychotic disorder and healthy controls at baseline (N = 293) and three years later at follow-up (N = 928). We assessed self-reported and observer-rated subclinical positive, negative, and depressive psychotic symptoms. Participants reported the number of SLEs in the preceding 6 months. A multilevel multivariate regression analysis revealed a positive association between the retrospectively assessed number of SLEs and symptom levels, regardless of vulnerability status (p <. 001 for all outcomes). The prospective analysis demonstrated that exposure to SLEs at baseline predicted higher levels of subclinical psychotic symptoms at follow-up. However, after controlling for the level of symptoms at baseline, these associations were no longer significant. Again, the vulnerability status did not modify these results. Nevertheless, siblings in our sample were approximating the end of the critical period for the development of psychotic disorder (mean age at baseline M = 29 and follow-up M = 34). The findings partly support the vulnerability-stress model of psychosis, yet do not confirm the role of familial risk in this association. SLEs may represent a risk factor for psychosis at a population level, thus supporting the continuity of the psychosis spectrum in terms of associated risk factors.
KW - Familial vulnerability
KW - Life events
KW - Psychosis risk
KW - Stress
KW - Subclinical psychotic symptoms
UR - http://www.scopus.com/inward/record.url?scp=85141776274&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.schres.2022.10.020
DO - https://doi.org/10.1016/j.schres.2022.10.020
M3 - Article
C2 - 36372001
SN - 0920-9964
VL - 250
SP - 92
EP - 99
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -